Back to Journals » OncoTargets and Therapy » Volume 9

Retraction

Authors Li J, Zhang Y, Wen B, Li M, Wang Y

Received 27 January 2016

Accepted for publication 27 January 2016

Published 4 February 2016 Volume 2016:9 Pages 613—614

DOI https://doi.org/10.2147/OTT.S105168


Li J-Z, Zhang Y, Wen B, Li M, Wang Y-J. Ability of PITX2 methylation to predict survival in patients with prostate cancer. OncoTargets Ther. 2015;8:3507–3512.

Large sections of text in this paper have been reused, albeit with minimal re-wording, without citation back to the source:
Li J-Z, Zhang Y, Wen B, Li M, and Wang Y-J have failed to provide any explanation for the unauthorised re-use of figures and tables from the 2014 publication, Vasiljevic N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT. DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med. 2014;8(9):1143–1150. 

This retraction relates to this paper

 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]